Treatment Advances

December 05, 2024

FDA reviews belantamab mafodotin for relapsed multiple myeloma, the decision is expected by July 2025.

November 28, 2024

Learn how BRCA gene mutations affect myeloma risk. Learn why genetic testing could be crucial for younger patients and those with family cancer history.

November 25, 2024

Do prior number of treatments and BTK inhibitor response affect CAR T-cell therapy success for MCL? Learn insights from Dr. Manali Kamdar.

November 20, 2024

If you are an adult with relapsed/refractory precursor B-cell ALL, learn how a new FDA-approved CAR T-cell therapy may be a treatment option for you.

November 19, 2024

Learn about revumenib, a newly FDA-approved treatment for relapsed/refractory acute leukemias with the KMT2A gene translocation.

November 19, 2024

Learn insights about how certain treatment combinations and a new scoring system impacted people with low-grade follicular lymphoma.

November 14, 2024

Learn about the microenvironment and how certain treatments target myeloma cells' interaction with the cells around them. 

November 12, 2024

Johnson & Johnson seeks FDA and EMA approval for Darzalex Faspro in high-risk smoldering myeloma, aiming to change the treatment paradigms.

November 08, 2024

Explore an innovative trial using Azer-cel, an allogeneic CAR T-cell therapy, for relapsed DLBCL patients, focusing on safety and effectiveness.

November 07, 2024

Learn what newly diagnosed multiple myeloma patients need to know about how induction (starting) therapy is evolving in the myeloma treatment landscape.